UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Blood, 2020-10, Vol.136 (18), p.2027-2037

2020

Volltextzugriff (PDF)

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

Annals of hematology, 2014, Vol.93 (1), p.89-98

2014

Volltextzugriff (PDF)

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients

British journal of haematology, 2011-12, Vol.155 (5), p.580-587

2011

Volltextzugriff (PDF)

A unified model of illusory and occluded contour interpolation

Vision research (Oxford), 2010-02, Vol.50 (3), p.284-299

2010

Volltextzugriff (PDF)

Surface interpolation and 3D relatability

Journal of vision (Charlottesville, Va.), 2008-11, Vol.8 (7), p.29.1-2919

2008

Volltextzugriff (PDF)

Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid

American journal of hematology, 2011-01, Vol.86 (1), p.25-30

2011

Volltextzugriff (PDF)

ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS7572-TPS7572

2019

Volltextzugriff (PDF)

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2012-11, Vol.120 (21), p.2979-2979

2012

Volltextzugriff (PDF)

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

Blood, 2013-11, Vol.122 (21), p.3218-3218

2013

Volltextzugriff (PDF)

A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8598-8598

2013

Volltextzugriff (PDF)

A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8098-8098

2012

Volltextzugriff (PDF)

Risk of skin cancer in multiple myeloma patients: A retrospective cohort study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e20044-e20044

2013

Volltextzugriff (PDF)

Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8599-8599

2013

Volltextzugriff (PDF)

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

Blood, 2012-11, Vol.120 (21), p.4063-4063

2012

Volltextzugriff (PDF)

Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3903-3911

2006

Volltextzugriff (PDF)

PROTOCOL FOR HUMAN EXPOSURE TO OPIOIDS AND CONCENTRATED MEDETOMIDINE USED IN FIELD APPLICATIONS

Journal of zoo and wildlife medicine, 2024-01, Vol.54 (4)

2024

Volltextzugriff (PDF)

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Blood, 2022-11, Vol.140 (Supplement 1), p.9325-9327

2022

Volltextzugriff (PDF)

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

The lancet. Diabetes & endocrinology, 2019-02, Vol.7 (2), p.128-139

2019

Volltextzugriff (PDF)

PLS3 missense variants affecting the actin-binding domains cause X-linked congenital diaphragmatic hernia and body-wall defects

American journal of human genetics, 2023-10, Vol.110 (10), p.1787-1803

2023

Volltextzugriff (PDF)

Feasibility and Patient Acceptance of Emergency Department-Based Influenza Vaccination in a Military Medical Center

Military medicine, 2016-08, Vol.181 (8), p.883-886

2016

Volltextzugriff (PDF)

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e167-e172

2018

Volltextzugriff (PDF)

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

Blood, 2021-11, Vol.138 (Supplement 1), p.1419-1419

2021

Volltextzugriff (PDF)

CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S267-S268

2022

Volltextzugriff (PDF)

Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S140

2022

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(12)
Adult
(7)
Male
(7)
Female
(6)
Aged
(5)
Biological And Medical Sciences
(5)
Hematology
(5)
Middle Aged
(5)
Aged, 80 And Over
(4)
Genetics & Heredity
(4)
Medical Sciences
(3)
Multiple Myeloma - Drug Therapy
(3)
Prognosis
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Biotechnology
(2)
Clinical Trials
(2)
Disease Progression
(2)
Drug Administration Schedule
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients

A unified model of illusory and occluded contour interpolation

Surface interpolation and 3D relatability

Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid

ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM)

A phase I/II study of carfilzomib (CFZ) as a replacement for bortezomib (BTZ) for multiple myeloma (MM) patients (Pts) progressing while receiving a BTZ-containing combination regimen

Risk of skin cancer in multiple myeloma patients: A retrospective cohort study

Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)

A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen

Activation of mitogen-activated protein kinase in estrogen receptor α-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor α-negative human breast tumors

PROTOCOL FOR HUMAN EXPOSURE TO OPIOIDS AND CONCENTRATED MEDETOMIDINE USED IN FIELD APPLICATIONS

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

PLS3 missense variants affecting the actin-binding domains cause X-linked congenital diaphragmatic hernia and body-wall defects

Mutations in the histamine N-methyltransferase gene, HNMT, are associated with nonsyndromic autosomal recessive intellectual disability

Feasibility and Patient Acceptance of Emergency Department-Based Influenza Vaccination in a Military Medical Center

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data

Poster: CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data

Suchergebnisse filtern